A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma

Nathan H. Fowler, Raisa M. Pinto, Chan Yoon Cheah, Sattva S. Neelapu, Francesco Turturro, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A Fanale, Luis E. Fayad, Sheryl G. Forbes, Janine Khan, Lei Feng, Felipe Samaniego, Loretta J. Nastoupil

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages3
JournalBlood
Volume126
Issue number23
Publication statusPublished - 3 Dec 2015
Externally publishedYes
Event57th Annual Meeting of the American-Society-of-Hematology - Orlando, United States
Duration: 5 Dec 20158 Dec 2015

Cite this

Fowler, N. H., Pinto, R. M., Cheah, C. Y., Neelapu, S. S., Turturro, F., Hagemeister, F. B., Romaguera, J. E., Fanale, M. A., Fayad, L. E., Forbes, S. G., Khan, J., Feng, L., Samaniego, F., & Nastoupil, L. J. (2015). A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood, 126(23).